Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397982 · ClinicalTrials.gov registry record · Phase 2
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
A Phase 2 study of Recurrent Melanoma and Stage IV Skin Melanoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT00397982: Completed Phase 2 study of Recurrent Melanoma and Stage IV Skin Melanoma, sponsored by National Cancer Institute (NCI).
NCT00397982 is a Phase 2 study of Recurrent Melanoma and Stage IV Skin Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00397982, a Phase 2 study of Recurrent Melanoma and Stage IV Skin Melanoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant melanoma by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.
Primary Outcome
Evaluated using Response Evaluation Criteria In Solid Tumor (RECIST) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Therapeutic Conventional Surgery
- BIOLOGICAL Bevacizumab
- DRUG Temsirolimus
Study Locations (2)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Virginia
- University of Virginia Cancer Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
What the finished NCT00397982 record still lists
NCT00397982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (90% lower).
The record links to 4 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00397982 reports a single indexed study location in Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT00397982 about?
NCT00397982 is a clinical study titled "Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma". This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal antibodies, such as bev...
What is the current status of trial NCT00397982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2008-01. Estimated completion is 2013-07.
What conditions does trial NCT00397982 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma.
What interventions are being tested in trial NCT00397982?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Bevacizumab (BIOLOGICAL), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00397982?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00397982 being conducted?
This trial has 2 study locations across Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00397982's enrollment target sits among peer trials
17 23rd of 23 higher than 1 of 23 other Recurrent Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia